2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 12: September 25, 2024 - New Targets in Atopic Dermatitis: What’s on Deck?
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, September 25, 2024
8 PM ET / 5 PM PT
New Targets in Atopic Dermatitis: What's on Deck?
This activity is supported by educational grants from Arcutis Biotherapeutics, Inc., Dermavant Sciences, Inc., Galderma, and Lilly USA, LLC.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
September 26, 2024
September 26, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the novel mechanisms of action of targeted atopic dermatitis (AD) therapies
Review the efficacy and safety from key clinical trials in emerging therapies for atopic dermatitis (AD)
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Tiffany Mayo, MD
Associate Professor
The University of Alabama at Birmingham
Dermatology Vice Chair of Diversity, Equity and Inclusion
Department Director of Clinical Trials
Birmingham, Alabama
Marc Serota, MD
CEO, MD Integrations
Faculty, University of Colorado
Denver, CO
Lisa Swanson, MD
Pediatric Dermatologist
Ada West Dermatology
Boise, ID
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board: Abbvie, Arcutis, BMS, Bodewell, Janssen, Lilly, Leo Novartis, Pfizer, UCB
Grant/Research Support: Acelyrin, BMS, ChemoCentryx, Galderma, Janssen, Lilly, Pfizer
Speakers Bureau: Arcutis, Amgen, BMS, Dermavant, Incyte, Sanofi Regeneron, Pfizer, Lilly, UCB
Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis
Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.